about
Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugsPharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant ProteinsMechanisms for quality control of misfolded transmembrane proteinsPharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptorsTrafficking and quality control of the gonadotropin releasing hormone receptor in health and diseaseThe constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation.A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptorTrafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.Congenital nephrogenic diabetes insipidus with a novel mutation in the aquaporin 2 gene.Aqp5 is a new transcriptional target of Dot1a and a regulator of Aqp2.X-Linked Recessive form of Nephrogenic Diabetes Insipidus in a 7-Year-Old Boy.Personalized biochemistry and biophysics.Assay strategies for identification of therapeutic leads that target protein traffickingNew insights into the dynamic regulation of water and acid-base balance by renal epithelial cells.Rescue of misrouted GnRHR mutants reveals its constitutive activityPax transactivation-domain interacting protein is required for urine concentration and osmotolerance in collecting duct epithelia.Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targetsNephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts.Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor.Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway.Familial forms of diabetes insipidus: clinical and molecular characteristics.Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system.Persistent severe polyuria after renal transplant.A novel mutation in AVPR2 causing congenital nephrogenic diabetes insipidus with complete resistance to antidiuretic hormone.Nephrogenic diabetes insipidus (NDI): clinical, laboratory and genetic characterization of five Brazilian patients.V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.N-Glycan-dependent and -independent quality control of human δ opioid receptor N-terminal variants.Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.Novel activators of aquaporin 2 membrane expression for the treatment of nephrogenic diabetes insipidus: less is more. Focus on "High-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concenHereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.Diabetes Insipidus.
P2860
Q21089948-60D1F62F-9657-45E8-947A-391CC2A48458Q21131288-786C136B-A5F1-45DC-AA6A-B63BBFD573B5Q26830475-7339810B-4D5F-4E0D-A16E-C43EFF80793FQ26992276-92342CB4-0C7C-4667-8D9C-9379F949B7AEQ28755163-3F80D702-50B4-4BCD-9BE3-90B1C62DC6BAQ33520239-1278DF67-BF4D-4252-9EA1-3D3F39B083F6Q33629937-81BF200F-9FB8-43AF-8FD6-47403C636AFDQ33699210-DF76D1A4-BA58-4622-929F-0287BF524D6DQ33717398-55267F0E-0D8E-4A07-905D-F878DBB7025DQ33733528-A26D8F02-B63B-4B65-83F1-648E444F8ED9Q34551326-09DE6843-63EF-4E81-81A4-FED988516392Q35549663-B38FEDF0-D613-4768-A81F-76FAE7CFA1C4Q35558034-76331D02-7CAB-4AC9-8524-F8B5E34A9825Q35661403-53671792-2815-4FAB-980C-0C5832C023A6Q35993741-00ED8635-8E72-4801-AB65-C84B222D0673Q36065485-CBA7018E-F865-457A-8A80-D579E238AEC1Q36249282-BA8C8B9C-FC3D-4BBA-9151-17B7B0F77941Q36316001-CF0B058C-1B4B-4DDA-9EF5-B98037E70437Q36724058-18CE4B85-C499-40FD-8200-ED33B8A676ECQ36957103-ED8D3EF7-A1C1-41F2-BD13-78268901F515Q37106881-C038B615-09CA-47F9-80AA-BDE90773308BQ37465201-EDF9D7D0-D3F1-406C-BB3A-FFCDF3B4F219Q37897472-B2F635D7-17ED-4B8E-AF14-BA84554D178DQ38429483-FB1D69D3-ECF4-4277-97DA-F8E38245A4A1Q38528569-A7132C0A-2EF3-4240-B76F-C5B9FFBE1E09Q38695316-051BF8F5-FA3A-484D-A05E-542EFB0D4E37Q39016449-241C104E-3EAF-45AC-B854-7D9C75D7CCE4Q40326415-C7DF8976-A6D7-413A-B751-508505E228D4Q40388054-8A17748E-5640-4F2D-8CA6-05316556A9AEQ40649339-EC0EC2EF-341B-491D-9CBF-781EF9B8A990Q41020895-039E9A9C-907E-42C8-9BB6-2329D11FEDC8Q42380620-B7FDD4C5-496D-45E4-A1A8-E90B5E3859C8Q42931603-C1FBB3BD-B94D-464F-A6FD-3118EB2C00D4Q47802729-0FF2D9A2-29C1-4E5E-97AB-8AD1AFACEF36Q51112288-0F90C6A8-5FE8-4A20-8BE7-B9518F33F659
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Nephrogenic diabetes insipidus
@ast
Nephrogenic diabetes insipidus
@en
Nephrogenic diabetes insipidus
@nl
type
label
Nephrogenic diabetes insipidus
@ast
Nephrogenic diabetes insipidus
@en
Nephrogenic diabetes insipidus
@nl
prefLabel
Nephrogenic diabetes insipidus
@ast
Nephrogenic diabetes insipidus
@en
Nephrogenic diabetes insipidus
@nl
P1476
Nephrogenic diabetes insipidus
@en
P2093
Daniel G Bichet
P304
P356
10.1053/J.ACKD.2006.01.006
P407
P577
2006-04-01T00:00:00Z